10/034746
Search results for Paper # 8

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
L11 and combretastatin	0

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L12

Refine Search

Recall Text | Clear

Search History

DATE: Tuesday, April 29, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L12	L11 and combretastatin	0	L12
L11	inhibit$ near10 nitric near oxide near synthase near10 immun$	47	L11
L10	nitric near oxide near synthase near10 immun$	175	L10
L9	(combretastatin or CA near 4 near P) near10 immun$	4	L9
L8	combretastatin near10 immun$	4	L8
L7	L4 and (combretastatin or CA near 4 near P) near10 (enhance$ or increase$) near5 immune$	2	L7
L6	L4 and (combretastatin or CA near 4 near P) near10 (enhance$ or incresae$) near5 immune$	2	L6
L5	L4 and (enhance$ or incresae$) near5 immune$	12	L5
L4	L3 and vascular	88	L4
L3	combretastatin$ or CA near 4 near P or combretastatin near A4	209	L3
L2	L1 and vascular	7	L2
L1	combretastin or CA near 4 near p or combretastin near A4	19	L1

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
(combretastatin or CA near 4 near P) near10 immun$	4

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L9

Refine Search

Recall Text | Clear

Your wildcard search against 10000 terms has yielded the results below.
The next term would be: ;
IMMUN$(IMMUNO-SUPPRESANT).P66-P132,P133-P140,P61-P65,P57-P60,P35-P55,P56-P56.
Your result set for the last L# is incomplete.
The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

Search History

DATE: Tuesday, April 29, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L9	(combretastatin or CA near 4 near P) near10 immun$	4	L9
L8	combretastatin near10 immun$	4	L8
L7	L4 and (combretastatin or CA near 4 near P) near10 (enhance$ or increase$) near5 immune$	2	L7
L6	L4 and (combretastatin or CA near 4 near P) near10 (enhance$ or incresae$) near5 immune$	2	L6
L5	L4 and (enhance$ or incresae$) near5 immune$	12	L5
L4	L3 and vascular	88	L4
L3	combretastatin$ or CA near 4 near P or combretastatin near A4	209	L3
L2	L1 and vascular	7	L2
L1	combretastin or CA near 4 near p or combretastin near A4	19	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 12 of 12 returned.

☐ 1. Document ID: US 20030055014 A1

L5: Entry 1 of 12 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030055014
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030055014 A1

TITLE: Inhibition of angiogenesis by nucleic acids

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bratzler, Robert L.	Concord	MA	US	

US-CL-CURRENT: 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20020160973 A1

L5: Entry 2 of 12 File: PGPB Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160973
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160973 A1

TITLE: Use of combretastatin A4 and its prodrugs as an immune enhancing therapy

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pero, Ronald W.	Sandgate	VT	US	
Lee, Francis Y.F.	Yardley	PA	US	
Edvardsen, Klaus	Lund		SE	
Sjogren, Hans Olov	Lund		SE	

US-CL-CURRENT: 514/44; 424/85.1, 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 20020119153 A1

L5: Entry 3 of 12 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119153
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020119153 A1

TITLE: Antibody conjugate formulations for selectively inhibiting VEGF

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thorpe, Philip E.	Dallas	TX	US	
Brekken, Rolf A.	Seattle	WA	US	

US-CL-CURRENT: 424/145.1; 424/133.1, 530/388.24

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 4. Document ID: US 20020114809 A1

L5: Entry 4 of 12 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020114809
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020114809 A1

TITLE: Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rubinfeld, Joseph	Danville	CA	US	
Chang, Lucy	San Mateo	CA	US	
DiMartino, Jorge	San Carlos	CA	US	

US-CL-CURRENT: 424/155.1; 424/277.1, 424/649, 514/171, 514/183, 514/254.07, 514/269, 514/27, 514/283, 514/34, 514/49

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 5. Document ID: US 6524583 B1

L5: Entry 5 of 12 File: USPT Feb 25, 2003

US-PAT-NO: 6524583
DOCUMENT-IDENTIFIER: US 6524583 B1

TITLE: Antibody methods for selectively inhibiting VEGF

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Brekken; Rolf A.	Seattle	WA		

US-CL-CURRENT: 424/145.1; 424/133.1, 424/135.1, 424/141.1, 530/387.1, 530/388.1, 530/388.15, 530/388.25, 530/809, 530/864, 530/865, 530/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 6. Document ID: US 6416758 B1

L5: Entry 6 of 12 File: USPT Jul 9, 2002

US-PAT-NO: 6416758
DOCUMENT-IDENTIFIER: US 6416758 B1
**** See image for Certificate of Correction ****

TITLE: Antibody conjugate kits for selectively inhibiting VEGF

DATE-ISSUED: July 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Brekken; Rolf A.	Seattle	WA		

US-CL-CURRENT: 424/145.1; 424/1.49, 424/1.53, 424/1.69, 424/133.1, 424/134.1, 424/135.1, 424/141.1, 424/142.1, 424/178.1 , 424/179.1, 424/181.1, 424/183.1, 424/195.11, 424/9.2, 424/9.3, 435/69.1, 435/69.6, 435/69.7, 435/7.23, 435/70.21, 435/810, 530/387.3, 530/388.1, 530/388.15, 530/388.24, 530/391.3, 530/391.7, 530/391.9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 7. Document ID: US 6406693 B1

L5: Entry 7 of 12 File: USPT Jun 18, 2002

US-PAT-NO: 6406693
DOCUMENT-IDENTIFIER: US 6406693 B1

TITLE: Cancer treatment methods using antibodies to aminophospholipids

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Ran; Sophia	Dallas	TX		

US-CL-CURRENT: 424/130.1; 424/132.1, 424/133.1, 424/135.1, 424/138.1, 424/141.1, 424/152.1, 424/184.1, 435/6, 530/387.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 8. Document ID: US 6342221 B1

L5: Entry 8 of 12 File: USPT Jan 29, 2002

US-PAT-NO: 6342221
DOCUMENT-IDENTIFIER: US 6342221 B1
**** See image for Certificate of Correction ****

TITLE: Antibody conjugate compositions for selectively inhibiting VEGF

DATE-ISSUED: January 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Brekken; Rolf A.	Seattle	WA		

US-CL-CURRENT: 424/178.1; 424/1.49, 424/1.53, 424/130.1, 424/179.1, 424/181.1, 424/183.1, 424/193.1, 424/195.11, 424/9.3 , 424/9.34, 424/9.6, 435/69.1, 435/7.1, 435/7.21, 435/7.23, 435/70.21, 435/810, 530/391.1, 530/391.3, 530/391.5, 530/391.7, 530/391.9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 9. Document ID: US 6342219 B1

L5: Entry 9 of 12 File: USPT Jan 29, 2002

US-PAT-NO: 6342219
DOCUMENT-IDENTIFIER: US 6342219 B1

TITLE: Antibody compositions for selectively inhibiting VEGF

DATE-ISSUED: January 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Brekken; Rolf A.	Seattle	WA		

US-CL-CURRENT: 424/145.1; 424/133.1, 424/134.1, 424/135.1, 424/141.1, 424/142.1, 424/143.1, 435/335, 435/69.1, 435/810, 530/387.1, 530/387.3, 530/388.1, 530/388.15, 530/388.23, 530/391.1, 530/391.3, 530/391.5, 530/391.7, 530/809, 530/864, 530/865, 530/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 10. Document ID: US 6312694 B1

L5: Entry 10 of 12 File: USPT Nov 6, 2001

US-PAT-NO: 6312694
DOCUMENT-IDENTIFIER: US 6312694 B1
**** See image for Certificate of Correction ****

TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Ran; Sophia	Dallas	TX		

US-CL-CURRENT: 424/178.1; 424/133.1, 424/134.1, 424/135.1, 424/136.1, 424/137.1, 424/141.1, 424/142.1, 424/143.1, 424/181.1, 424/193.1, 514/12, 530/387.1, 530/388.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Draw Desc | Image | KWIC

☐ 11. Document ID: WO 2058535 A2

L5: Entry 11 of 12 File: EPAB Aug 1, 2002

PUB-NO: WO002058535A2
DOCUMENT-IDENTIFIER: WO 2058535 A2
TITLE: USE OF COMBRETASTATIN A4 AND ITS PRODRUGS AS AN IMMUNE ENHANCING THERAPY

PUBN-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
PERO, RONALD W	
LEE, FRANCIS Y F	
EDVARDSEN, KLAUS	
SJOEGREN, HANS OLOV	

INT-CL (IPC): A61 B 0/

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Draw Desc | Image | KWIC

☐ 12. Document ID: WO 200258535 A2 US 20020160973 A1

L5: Entry 12 of 12 File: DWPI Aug 1, 2002

DERWENT-ACC-NO: 2002-732689
DERWENT-WEEK: 200279
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Use of combretastatin A4 and/or its prodrugs as an immune enhancing therapy for treating immunosuppression

INVENTOR: EDVARDSEN, K; LEE, F Y F ; PERO, R W ; SJOGREN, H O ; SJOEGREN, H O

PRIORITY-DATA: 2000US-258283P (December 26, 2000), 2001US-0034746 (December 26,

2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200258535 A2	August 1, 2002	E	046	A61B000/00
US 20020160973 A1	October 31, 2002		000	A61K048/00

INT-CL (IPC): A61 B 0/00; A61 K 38/17; A61 K 38/19; A61 K 48/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

Generate Collection | Print

Terms	Documents
L4 and (enhance$ or incresae$) near5 immune$	12

Display Format: - Change Format

Previous Page Next Page

```
set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,6,55,154,155,156,312,399,biotech,biosci
>>>         135 is unauthorized
```

```
 Set  Items  Description
      ---  -----  -----------
? s combretastatin? and immun?
>>>File 5 processing for IMMUN? stopped at IMMUNODEPRESSED
>>>File 55 processing for IMMUN? stopped at IMMUNOGENICITYOF
>>>File 154 processing for IMMUN? stopped at IMMUNOFLOW
>>>File 155 processing for IMMUN? stopped at IMMUNOCLUSTERED
>>>File 156 processing for IMMUN? stopped at IMMUNOPOTENTIATOR
>>>File 399 processing for IMMUN? stopped at IMMUNOMUDALATORY
Processing
>>>File 34 processing for IMMUN? stopped at IMMUNOFLURESCENCE
Processed  10 of  34 files ...
>>>File 71 processing for IMMUN? stopped at IMMUNORECTIVITY
>>>File 73 processing for IMMUN? stopped at IMMUNOCOMPROMISING
>>>File 144 processing for IMMUN? stopped at IMMUNODENSITY
Processing
Processed  20 of  34 files ...
>>>File 50 processing for IMMUN? stopped at IMMUNOPRECIPITATING
Completed processing all files
           1905  COMBRETASTATIN?
        6393344  IMMUN?
     S1      76  COMBRETASTATIN? AND IMMUN?
? s s1 and immunosuppression
             76  S1
         212188  IMMUNOSUPPRESSION
     S2       0  S1 AND IMMUNOSUPPRESSION
? s combretastatin? and immunosuppression
           1905  COMBRETASTATIN?
         212188  IMMUNOSUPPRESSION
     S3       0  COMBRETASTATIN? AND IMMUNOSUPPRESSION
? s combretastatin? and immunotherap?
           1905  COMBRETASTATIN?
         273232  IMMUNOTHERAP?
     S4      12  COMBRETASTATIN? AND IMMUNOTHERAP?
? rd s4
...completed examining records
     S5       8  RD S4 (unique items)
? d s5/9/1-8
     Display 5/9/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11877151   BIOSIS NO.: 199900123260
Immunotherapy combined with antiangiogenic drugs.
AUTHOR: Sjogren Hans O(a)
AUTHOR ADDRESS: (a)Tumor Immunol. Unit, CMB, Wallenberg Lab., Univ. Lund,
  Lund**Sweden
JOURNAL: Tumor Biology  19 (SUPPL. 2):p5 Aug., 1998
CONFERENCE/MEETING: 26th Meeting of the International Society for
Oncodevelopmental Biology and Medicine  Umea, Sweden  August 30-September
4, 1998
ISSN: 1010-4283
RECORD TYPE: Citation
LANGUAGE: English
REGISTRY NUMBERS: 82855-09-2: COMBRETASTATIN; 86090-08-6: ANGIOSTATIN
DESCRIPTORS:
  MAJOR CONCEPTS: Immune System (Chemical Coordination and Homeostasis);
    Pharmacology; Tumor Biology

                                    -more-
?
     Display 5/9/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
```

(c) 2003 BIOSIS. All rts. reserv.
BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: rat (Muridae)
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates
DISEASES: colon carcinoma--digestive system disease, neoplastic disease
CHEMICALS & BIOCHEMICALS: angiostatin--antiangiogenic; **combretastatin**--antiangiogenic
MISCELLANEOUS TERMS: **immunotherapy**; Meeting Abstract
ALTERNATE INDEXING: Carcinoma (MeSH); Colonic Neoplasms (MeSH)
CONCEPT CODES:
24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy
12512 Pathology, General and Miscellaneous-Therapy (1971-)
14006 Digestive System-Pathology
14508 Cardiovascular System-Blood Vessel Pathology
22010 Pharmacology-Cardiovascular System
34502 Immunology and Immunochemistry-General; Methods

-more-

?
Display 5/9/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.
00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals
10060 Biochemical Studies-General
BIOSYSTEMATIC CODES:
86375 Muridae

- end of record -

?
Display 5/9/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137119643 CA: 137(9)119643z PATENT
Methods using a combretastatin compound combined with an antitumor agent for modulating tumor growth and metastasis
INVENTOR(AUTHOR): Lee, Francis Y.; Peck, Ronald; Chaplin, David; Pero, Ronald; Edvardsen, Klaus
LOCATION: USA
ASSIGNEE: Bristol-Myers Squibb Company; Oxigene, Inc.
PATENT: PCT International ; WO 200256692 A1 DATE: 20020725
APPLICATION: WO 2001US50261 (20011220) *US PV258195 (20001222)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A01N-057/00A; A61K-038/00B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM

-more-

?
Display 5/9/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA201006 Pharmacology

CA263XXX Pharmaceuticals
IDENTIFIERS: combretastatin compd antitumor agent combination neoplasm metastasis treatment
DESCRIPTORS:
Nutrients...
anti-; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Antitumor agents...
antibiotic; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Estrogens...
antiestrogens; combretastatin compd. combined with antitumor agent for

-more-

?

Display 5/9/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

modulating tumor growth and metastasis
Antibiotics...
antitumor; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Pseudomonas...
BR96-sFv-PE40 immunoconjugate; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Mammary gland... Ovary,neoplasm...
carcinoma; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Intestine,neoplasm...
colon; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Alkylating agents,biological... Antitumor agents... Circulation... Drug delivery systems... Drug interactions... Human... Immunotherapy... Neoplasm ... Pharmacokinetics... Radiotherapy... Taxanes...
combretastatin compd. combined with antitumor agent for modulating

-more-

?

Display 5/9/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

tumor growth and metastasis
Toxins...
exotoxins, BR96-sFv-PE40 immunoconjugate; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Sarcoma...
fibrosarcoma; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Drug delivery systems...
immunotoxins; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Neoplasm...
metastasis; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Mitosis...
mitotic inhibitors; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis

-more-

?

Display 5/9/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.
Antibodies...
monoclonal, conjugates, BR96-sFv-PE40 immunoconjugate; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Mammary gland...
neoplasm; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Drug delivery systems...
prodrugs; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
Drug interactions...
synergistic; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
CAS REGISTRY NUMBERS:
50-07-7 50-18-0 50-76-0 51-21-8 51-75-2 57-22-7 58-05-9 59-05-2
147-94-4 148-82-3 154-93-8 305-03-3 595-33-5 865-21-4 3778-73-2
4342-03-4 11056-06-7 13010-47-4 15663-27-1 20830-81-3 21679-14-1

-more-

?
Display 5/9/2 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.
23214-92-8 25316-40-9 33069-62-4 33419-42-0 41575-94-4 58957-92-9
61825-94-3 71486-22-1 74381-53-6 74578-38-4 95058-81-4 100286-90-6
107868-30-4 109971-63-3 114977-28-5 117048-59-6 117091-64-2
120511-73-1 121584-18-7 123948-87-8 146426-40-6 168555-66-6
180288-69-1 184475-35-2 252916-29-3 288847-34-7 443913-73-3
combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
13010-20-3D 109971-63-3D 117048-59-6D derivs., combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
143180-75-0 inhibitors; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis
9039-48-9 nonsteroidal inhibitors; combretastatin compd. combined with antitumor agent for modulating tumor growth and metastasis

- end of record -

?
Display 5/9/3 (Item 1 from file: 8)
DIALOG(R)File 8:Ei Compendex(R)
(c) 2003 Elsevier Eng. Info. Inc. All rts. reserv.

05339745 E.I. No: EIP99084755247
Title: Examples of adjuvant treatment enhancing the antitumor effect of photodynamic therapy
Author: Korbelik, Mladen; Cecic, Ivana; Sun, Jinghai; Chaplin, David J.
Corporate Source: British Columbia Cancer Agency, Vancouver, BC, Can
Conference Title: Proceedings of the 1999 Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy VIII
Conference Location: San Jose, CA, USA Conference Date: 19990123-19990124
Sponsor: SPIE; IBOS
E.I. Conference No.: 55251
Source: Proceedings of SPIE - The International Society for Optical Engineering v 3592 1999. p 65-72
Publication Year: 1999
CODEN: PSISDG ISSN: 0277-786X

-more-

?
Display 5/9/3 (Item 1 from file: 8)
DIALOG(R)File 8:Ei Compendex(R)

Language: English
Document Type: JA; (Journal Article) Treatment: L; (Literature Review/Bibliography); X; (Experimental)
Journal Announcement: 9909W5
Abstract: Strategies for improving the clinical efficacy of photodynamic therapy (PDT) in treatment of solid cancers include applications of different types of adjuvant treatments in addition to this modality that may result in superior therapeutic outcome. Examples of such an approach investigated using mouse tumor models are presented in this report. It is shown that the cures of PDT treated subcutaneous tumors can be substantially improved by adjuvant therapy with: metoclopramide (enhancement of cancer cell apoptosis), **combretastatin** A-4 (selective destruction of tumor neovasculature), Roussin's Black Salt (light activated tumor localized release of nitric oxide), or dendritic cell-based adoptive **immunotherapy** (immune rejection of treated tumor). (Author abstract) 51 Refs.
Descriptors: *Photodynamic therapy; Oncology; Immunology

-more-

?
Display 5/9/3 (Item 1 from file: 8)
DIALOG(R)File 8:Ei Compendex(R)

Identifiers: Antitumor effects; Roussin's black salt
Classification Codes:
461.9.1 (Immunology)
461.6 (Medicine); 741.1 (Light/Optics); 461.9 (Biology)
461 (Biotechnology); 741 (Optics & Optical Devices)
46 (BIOENGINEERING); 74 (OPTICAL TECHNOLOGY)

- end of record -

?
Display 5/9/4 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE

01808445 2001170229
Eradication of colorectal xenografts by combined radioimmunotherapy and **combretastatin** A-4 3-O-phosphate
Pedley R.B.; Hill S.A.; Boxer G.M.; Flynn A.A.; Boden R.; Watson R.; Dearling J.; Chaplin D.J.; Begent R.H.J.
ADDRESS: R.B. Pedley, Department of Oncology, Royal Free and Univ. Coll. Med. Sch., Royal Free Campus, Rowland Hill Street, London NW3 2PF , United Kingdom
Journal: Cancer Research, 61/12 (4716-4722), 2001, United States
PUBLICATION DATE: June 15, 2001
CODEN: CNREA
ISSN: 0008-5472
DOCUMENT TYPE: Article
LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 33

-more-

?
Display 5/9/4 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE

Solid tumors have a heterogeneous pathophysiology, which has a major impact on therapy. Using SW1222 colorectal xenografts grown in nude mice, we have

shown that antibody-targeted radioimmunotherapy (RIT) effectively treated the well-perfused tumor rim, producing regressions for (similar)35 days, but was less effective at the more hypoxic center. By 72 h after RIT, the number of apoptotic cells rose from an overall value of 1% in untreated tumors to 35% at the tumor periphery and 10% at the center. The antivascular agent disodium **combretastatin** A-4 3-O-phosphate (CA4-P) rapidly reduced tumor blood flow to 62% of control values by 1 h, 23% by 3 h, and between 32-36% from 6 to 24 h after administration. This created central hemorrhagic necrosis, but a peripheral rim of cells continued to grow, and survival was unaffected. Changes in the pattern of perfusion across the tumor over time were zonal. Untreated mice showed perfusion throughout the tumor, with greatest activity at the rim. There was an overall reduction at 1 h, and total cessation of central perfusion from 3 h onward. A narrow peripheral rim of perfusion was always present, which increased in intensity and extent between 6 and 24 h, either through

-more-

?

Display 5/9/4 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE

reperfusion or new vessel growth. Combining these two complementary therapies (7.4 MBq SUP131I-labeled anti-carcinoembryonic antigen IgG i.v. plus a single 200 mg/kg dose of CA4-P i.p.) produced complete cures in five of six mice for >9 months. Allowing maximal tumor localization of antibody (48 h) before blood flow inhibition by CA4-P increased tumor retention by two to three times control levels by 96 h without altering normal tissue levels, as confirmed by gamma counting and phosphor image analysis. The success of this combined, synergistic therapy was probably the result of several factors: (a) the killing of tumor cells in the outer, radiosensitive region by targeted radiotherapy; (b) enhancement of RIT by entrapment of additional radioantibody after **combretastatin**-induced vessel collapse; and (c) destruction of the central, more hypoxic and radioresistant region by CA4-P. This work demonstrates the need to consider cancer treatment in a biologically heterogeneous setting, if results are to be effectively translated to the clinic.

CLASSIFICATION CODE AND DESCRIPTION:

-more-

?

Display 5/9/4 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE

87.4.2 - CANCER RESEARCH / TREATMENT / Radiotherapy
87.4.3 - CANCER RESEARCH / TREATMENT / **Immunotherapy**
87.4.11 - CANCER RESEARCH / TREATMENT / Treatment Monitoring and Evaluation
86.9.2 - IMMUNOLOGY AND INFECTIOUS DISEASES / TUMOUR IMMUNOLOGY / Immune Response

- end of record -

?

Display 5/9/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11796913 EMBASE No: 2002367661
Potential of DMXAA combination therapy for solid tumors
Baguley B.C.; Wilson W.R.
B.C. Baguley, Auckland Cancer Society Res. Centre, The University of Auckland, Auckland New Zealand
AUTHOR EMAIL: b.baguley@auckland.ac.nz
Expert Review of Anticancer Therapy (EXPERT REV. ANTICANCER THER.) (

United Kingdom) 2002, 2/5 (593-603)
CODEN: ERATB ISSN: 1473-7140
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 84

DMXAA is one of the first examples of a new class of anticancer agents that attack existing tumor blood vessels and thus deprives tumor fissue of an adequate blood supply. Its mechanism of action appears to rely on the

-more-

?
Display 5/9/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

Induction within tumor tissue of cytokines, such as tumor necrosis factor. In experimental tumors, DMXAA interacts productively with radiation, hyperthermia and a number of chemotherapeutic drugs. This review discusses the mechanisms underlying such interactions and how these might be exploited in clinical cancer treatment.

BRAND NAME/MANUFACTURER NAME: sr 4233
DRUG DESCRIPTORS:
*5,6 dimethylxanthenone 4 acetic acid--adverse drug reaction--ae; *5,6 dimethylxanthenone 4 acetic acid--clinical trial--ct; *5,6 dimethylxanthenone 4 acetic acid--drug analysis--an; *5,6 dimethylxanthenone 4 acetic acid--drug combination--cb; *5,6 dimethylxanthenone 4 acetic acid--drug interaction--it; *5,6 dimethylxanthenone 4 acetic acid--drug therapy--dt; *5,6 dimethylxanthenone 4 acetic acid--drug toxicity--to; *5,6 dimethylxanthenone 4 acetic acid --pharmacology--pd
antineoplastic agent--adverse drug reaction--ae; antineoplastic agent

-more-

?
Display 5/9/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

--clinical trial--ct; antineoplastic agent--drug analysis--an; antineoplastic agent--drug combination--cb; antineoplastic agent--drug interaction--it; antineoplastic agent--drug therapy--dt; antineoplastic agent--drug toxicity--to; antineoplastic agent--pharmacology--pd; cytokine --endogenous compound--ec; tumor necrosis factor--endogenous compound--ec; mitoflaxone--drug analysis--an; mitoflaxone--drug therapy--dt; mitoflaxone --pharmacology--pd; antiinflammatory agent--drug analysis--an; antiinflammatory agent--drug therapy--dt; antiinflammatory agent --pharmacology--pd; xanthone 4 acetic acid--drug analysis--an; xanthone 4 acetic acid--drug therapy--dt; xanthone 4 acetic acid--pharmacology--pd; colchicine--pharmacology--pd; vinblastine--pharmacology--pd; **combretastatin** A4--clinical trial--ct; **combretastatin** A4--drug therapy--dt; 5 hydroxyindoleacetic acid--endogenous compound--ec; endotoxin --endogenous compound--ec; 1,2,3 benzotriazine derivative--clinical trial --ct; 1,2,3 benzotriazine derivative--drug combination--cb; 1,2,3 benzotriazine derivative--drug interaction--it; 1,2,3 benzotriazine derivative--drug therapy--dt; tirapazamine--clinical trial--ct;

-more-

?
Display 5/9/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

tirapazamine--drug interaction--it; tirapazamine--drug therapy--dt; 1,4 bis[[2 (dimethylamino n oxide)ethyl]amino] 5,8 dihydroxyanthraquinone

--clinical trial--ct; 1,4 bis[[2 (dimethylamino n oxide)ethyl]amino] 5,8 dihydroxyanthraquinone--drug combination--cb; 1,4 bis[[2 (dimethylamino n oxide)ethyl]amino] 5,8 dihydroxyanthraquinone--drug interaction--it; 1,4 bis[[2 (dimethylamino n oxide)ethyl]amino] 5,8 dihydroxyanthraquinone--drug therapy--dt; benzamide derivative--drug combination--cb; benzamide derivative--drug interaction--it; benzamide derivative--drug therapy--dt; benzamide derivative--pharmacology--pd; cytotoxic agent--drug combination --cb; cytotoxic agent--drug interaction--it; cytotoxic agent--drug therapy --dt; cytotoxic agent--drug toxicity--to; cytotoxic agent--pharmacokinetics --pk; cytotoxic agent--pharmacology--pd; melphalan--drug combination--cb; melphalan--drug interaction--it; melphalan--drug therapy--dt; melphalan --drug toxicity--to; melphalan--pharmacokinetics--pk; melphalan --pharmacology--pd; paclitaxel--drug combination--cb; paclitaxel--drug interaction--it; paclitaxel--drug therapy--dt; paclitaxel--pharmacokinetics --pk; paclitaxel--pharmacology--pd; docetaxel--drug combination--cb;

-more-

?

Display 5/9/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

docetaxel--drug interaction--it; docetaxel--drug therapy--dt; docetaxel --pharmacology--pd; vincristine--drug combination--cb; vincristine--drug interaction--it; vincristine--drug therapy--dt; vincristine--pharmacology --pd; etoposide--drug combination--cb; etoposide--drug interaction--it; etoposide--drug therapy--dt; etoposide--pharmacology--pd; carboplatin--drug combination--cb; carboplatin--drug interaction--it; carboplatin--drug therapy--dt; carboplatin--pharmacokinetics--pk; carboplatin--pharmacology --pd; cyclophosphamide--drug combination--cb; cyclophosphamide--drug interaction--it; cyclophosphamide--drug therapy--dt; cyclophosphamide --pharmacology--pd; doxorubicin--drug combination--cb; doxorubicin--drug interaction--it; doxorubicin--drug therapy--dt; doxorubicin--pharmacology --pd; cisplatin--drug combination--cb; cisplatin--drug interaction--it; cisplatin--drug therapy--dt; cisplatin--pharmacology--pd; fluorouracil --drug combination--cb; fluorouracil--drug interaction--it; fluorouracil --drug therapy--dt; fluorouracil--pharmacology--pd; angiogenesis inhibitor --drug combination--cb; angiogenesis inhibitor--drug interaction--it; angiogenesis inhibitor--drug therapy--dt; angiogenesis inhibitor

-more-

?

Display 5/9/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

--pharmacology--pd; thalidomide--drug combination--cb; thalidomide--drug interaction--it; thalidomide--drug therapy--dt; thalidomide--pharmacology --pd; unindexed drug
MEDICAL DESCRIPTORS:
*solid tumor--drug therapy--dt; *solid tumor--radiotherapy--rt
drug classification; tumor vascularization; cancer tissue; drug mechanism; experimental neoplasm--drug therapy--dt; cancer radiotherapy; hyperthermia; cancer chemotherapy; drug structure; drug activity; side effect--side effect--si; drug potentiation; drug blood level; area under the curve; drug tolerability; radioimmunotherapy; gene therapy; cancer **immunotherapy**; human; nonhuman; clinical trial; controlled study; review
CAS REGISTRY NO.: 87626-55-9 (mitoflaxone); 64-86-8 (colchicine); 865-21-4 (vinblastine); 117048-59-6 (**combretastatin** A4); 1321-73-9, 54-16-0 (5 hydroxyindoleacetic acid); 27314-97-2 (tirapazamine); 136470-65-0 (1,4 bis[[2 (dimethylamino n oxide)ethyl]amino] 5,8 dihydroxyanthraquinone); 148-82-3 (melphalan); 33069-62-4 (paclitaxel); 114977-28-5 (docetaxel); 57-22-7 (vincristine); 33419-42-0 (etoposide);

-more-

?
Display 5/9/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

41575-94-4 (carboplatin); 50-18-0 (cyclophosphamide); 23214-92-8, 25316-40-9 (doxorubicin); 15663-27-1, 26035-31-4, 96081-74-2 (cisplatin); 51-21-8 (fluorouracil); 50-35-1 (thalidomide
SECTION HEADINGS:
014 Radiology
016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reaction Titles

- end of record -

?
Display 5/9/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

11445087 EMBASE No: 2002016166
From biology to therapy
VON DER BIOLOGIE ZUR THERAPIE
Azemar M.; Hildenbrand B.
Dr. M. Azemar, Klinik fur Tumorbiologie, Albert-Ludwigs-Universitat Freiburg, Hugstetter Strasse 55, 79106 Freiburg Germany
Klinikarzt (KLINIKARTZ) (Germany) 2001, 30/12 (322-327)
CODEN: KLINF ISSN: 0341-2350
DOCUMENT TYPE: Journal ; Review
LANGUAGE: GERMAN SUMMARY LANGUAGE: ENGLISH; GERMAN

Metastases remain the main cause of death from solid tumours, the most common neoplasias. The initial successes of chemotherapies achieved in the middle of the 20SUPth century were followed by years of disappointment and frustration. The present article describes the major steps in the development and metastasization of tumours on the basis of the latest

-more-

?
Display 5/9/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

results of relevant research. Also discussed are new therapeutic options based on the latest data. These include antiangiogenesis, antisense oligoneucleotides, signal transduction inhibitors, and **immunotherapeutic** approaches. Many of these experimental treatment strategies are currently in advanced stages of clinical development, and will supplement established therapeutic options in future.

BRAND NAME/MANUFACTURER NAME: im 842; tnp 470; ae 941; su 5416; su 6668; ptk 787; zk 222584; g 3139; isis 3521; isis 5132; isis 2503; mg 98; apc 8015; qs 21
DRUG DESCRIPTORS:
marimastat; ae 941; fumagillol chloroacetylcarbamate; thalidomide; squalamine; **combretastatin** A4; endostatin; su 6668; 1 (4 chloroanilino) 4 (4 pyridylmethyl)phthalazine; vasculotropin antibody; alpha interferon; monoclonal antibody lm 609; tetrathiomolybdic acid; antineoplastic agent; g 3139; isis 3521; cgp 69846a; isis 2503; gene expression modulator 231; antisense oligonucleotide; granulocyte macrophage

-more-

?
Display 5/9/6 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.
colony stimulating factor--clinical trial--ct; glycoprotein gp 100
--clinical trial--ct; qs 21--clinical trial--ct; glycoprotein gp 96
--clinical trial--ct; melan A--clinical trial--ct; unclassified drug; 3
[(3,5 dimethyl 1h pyrrol 2 yl)methylene] 1,3 dihydro 2h indol 2 one
MEDICAL DESCRIPTORS:
*metastasis
pathogenesis; angiogenesis; molecular biology; malignant transformation;
signal transduction; cancer **immunotherapy**; drug efficacy; cancer
research; human; major clinical study; clinical trial; review
DRUG TERMS (UNCONTROLLED): 3 [(4,5 dimethyl 1h pyrrol 2 yl)methylene] 1,3
dihydro 2h indol 2 one; im 842; mg 98; apc 8015--clinical trial--ct
CAS REGISTRY NO.: 154039-60-8 (marimastat); 129298-91-5 (fumagillol
chloroacetylcarbamate); 50-35-1 (thalidomide); 148717-90-2, 160022-48-0
(squalamine); 117048-59-6 (**combretastatin** A4); 187888-07-9 (
endostatin); 252916-29-3 (su 6668); 212142-18-2 (1 (4 chloroanilino) 4
(4 pyridylmethyl)phthalazine); 13718-35-9, 16330-92-0 (
tetrathiomolybdic acid); 190977-41-4 (g 3139); 151879-73-1 (isis 3521);

-more-

?
Display 5/9/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.
177075-18-2 (cgp 69846a); 149957-14-2 (isis 2503); 141256-04-4 (qs 21);
186610-95-7 (3 [(3,5 dimethyl 1h pyrrol 2 yl)methylene] 1,3 dihydro 2h
indol 2 one
SECTION HEADINGS:
016 Cancer
037 Drug Literature Index

- end of record -

?
Display 5/9/7 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

10784849 EMBASE No: 2000261387
Canadian sarcoma group workshop sarcomas: Molecular markers to
therapeutics, 26-27 February 2000, Toronto, Canada
Bramwell V.; Andrulis I.; Bell R.; Eisenhauer E.; Fornasier V.; Kandel R.
; O'Sullivan B.; Temple W.; Turcotte R.; Wunder J.
V. Bramwell, London Regional Cancer Centre, 790 Commissioners Road East,
London, Ont. N6A 4L6 Canada
Sarcoma (SARCOMA) (United Kingdom) 2000, 4/1-2 (67-73)
CODEN: SARCF ISSN: 1357-714X
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH
BRAND NAME/MANUFACTURER NAME: et 743; bbr 3464; ptk 787
DRUG DESCRIPTORS:
*irinotecan--clinical trial--ct; *irinotecan--drug therapy--dt; *
ecteinascidin 743--clinical trial--ct; *ecteinascidin 743--drug therapy--dt
; *anthraquinone derivative--clinical trial--ct; *anthraquinone derivative

-more-

?
Display 5/9/7 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.
--drug therapy--dt; *DNA topoisomerase inhibitor--clinical trial--ct; *DNA
topoisomerase inhibitor--drug combination--cb; *DNA topoisomerase inhibitor
--drug interaction--it; *DNA topoisomerase inhibitor--drug therapy--dt

cisplatin--drug combination--cb; cisplatin--drug interaction--it; cisplatin --drug therapy--dt; cyclophosphamide--drug combination--cb; cyclophosphamide--drug interaction--it; cyclophosphamide--drug therapy--dt; bbr 3464--clinical trial--ct; bbr 3464--drug therapy--dt; **combretastatin** A4--clinical trial--ct; **combretastatin** A4--drug therapy--dt; unclassified drug
MEDICAL DESCRIPTORS:
*sarcoma--diagnosis--di; *sarcoma--drug therapy--dt; *sarcoma--epidemiology --ep; *sarcoma--radiotherapy--rt; *sarcoma--surgery--su; *soft tissue sarcoma--diagnosis--di; *soft tissue sarcoma--drug therapy--dt; *soft tissue sarcoma--epidemiology--ep; *soft tissue sarcoma--radiotherapy--rt; * soft tissue sarcoma--surgery--su
molecular biology; cancer cytodiagnosis; cancer **immunotherapy**; quality of life; human; clinical trial; phase 2 clinical trial; human

-more-

?
Display 5/9/7 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

tissue; human cell; conference paper; priority journal
DRUG TERMS (UNCONTROLLED): ptk 787--drug analysis--an; ptk 787--drug development--dv
CAS REGISTRY NO.: 100286-90-6 (irinotecan); 114899-77-3 (ecteinascidin 743) ; 15663-27-1, 26035-31-4, 96081-74-2 (cisplatin); 50-18-0 (cyclophosphamide); 172903-07-0 (bbr 3464); 117048-59-6 (**combretastatin** A4)
SECTION HEADINGS:
016 Cancer
037 Drug Literature Index

- end of record -

?
Display 5/9/8 (Item 1 from file: 266)
DIALOG(R)File 266:FEDRIP

00310425
IDENTIFYING NO.: 1R43CA88583-01A1 AGENCY CODE: CRISP
Potent Monoclonal Antibody Drug Conjugates
PRINCIPAL INVESTIGATOR: SENTER, PETER D
ADDRESS: SEATTLE GENETICS INC 21823 30TH DR. SE BOTHELL, WA 98021
PERFORMING ORG.: SEATTLE GENETICS, INC., BOTHELL, WASHINGTON
SPONSORING ORG.: NATIONAL CANCER INSTITUTE
FY : 2001 TYPE OF AWARD: New Award (Type 1)
SUMMARY: Phase I and II clinical trials with BR96-doxorubicin, an immunoconjugate that re cognizes receptors on human carcinomas, have demonstrated that the monoclonal an tibody component, BR96, is capable of safely delivering active doxorubicin to tu mor masses, albeit at concentrations that are sub-optimal. We propose to constru ct and test significantly improved conjugates consisting of highly potent drugs attached to BR96 through a new generation of optimized peptide-based linkers. Th e resulting conjugates should be stable in serum, but labile

-more-

?
Display 5/9/8 (Item 1 from file: 266)
DIALOG(R)File 266:FEDRIP

inside tumor cell l ysosomes, leading to the release of active drug at the target site. The drugs wi ll consist of two classes. Minor groove binders containing a distamycin unit wil l be attached to the DNA alkylator cyclopropylpyrroloindole, forming a construct that will covalently modify

the DNA of target cancer cells. The second drug wil l be **combretastatin** A4, a potent antimitotic agent that acts both on tumor cells and tumor vasculature. It is expected that conditionally stable conjugates prep ared with these agents will be potent and capable of effecting antitumor activit ies at biologically relevant doses. The aims of the proposed study are to synthe size potent drug derivatives, link them to BR96 and to a ,monoclonal antibody ag ainst the CD40 antigen, and evaluate their stability characteristics in vitro cy totoxic activities, and in vivo toxicities and activities in nude mice with huma n tumor xenografts. PROPOSED COMMERCIAL APPLICATIONS: There is a very large unme t clinical need for treating carcinomas of the breast, lung, colon, and prostate . The BR96 antibody recognizes the Lewis-Y antigen, which is widely expressed on these tumors. Using the BR96 antibody for the delivery of potent drugs to

-more-

```
?
      Display 5/9/8     (Item 1 from file: 266)
DIALOG(R)File 266:FEDRIP
Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.
```

tumor s may lead to pronounced anticancer activity with acceptable levels of systemic toxicity. This would constitute a major advancement in the clinical treatment of cancer.

DESCRIPTORS: athymic mouse; antimitotic; antineoplastic; lysosome; chemical conjugate; immunoconjugate; monoclonal antibody; immunopharmacology; neoplasm /cancer **immunotherapy**; antitumor antibody; lung neoplasm; neoplasm /cancer pharmacology; high performance liquid chromatography; cathepsin B; nonhuman therapy evaluation; SDS polyacrylamide gel electrophoresis; cell line; enzyme activity; angiogenesis inhibitor

- end of display -

```
?
>>>Page beyond end of display invalid
? s combretastatin? and nitric (n) oxide
Processed  30 of  34 files ...
Processing
Completed processing all files
           1905  COMBRETASTATIN?
         655754  NITRIC
        2943712  OXIDE
         575988  NITRIC(N)OXIDE
      S6      61  COMBRETASTATIN? AND NITRIC (N) OXIDE
? s s6 and synthase
             61  S6
         630955  SYNTHASE
      S7      41  S6 AND SYNTHASE
? rd s7
...completed examining records
      S8      10  RD S7 (unique items)
? d s8/3/1-10
      Display 8/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

14159823   BIOSIS NO.: 200300153852
The First International Conference on Vascular Targeting: Meeting overview.
AUTHOR: Thorpe Philip E(a); Chaplin David J; Blakey David C
AUTHOR ADDRESS: (a)Department of Pharmacology, University of Texas
  Southwestern Medical Center, Dallas, TX, 75390, USA**USA E-Mail:
  philip.thorpe@utsouthwestern.edu
JOURNAL: Cancer Research  63 (5):p1144-1147 March 1 2003 2003
MEDIUM: print
ISSN: 0008-5472
```

RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 8/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

14062690 BIOSIS NO.: 200300056719
Enhancement of vascular targeting by inhibitors of **nitric oxide synthase.**
AUTHOR: Davis Peter D(a); Tozer Gillian M; Naylor Matthew A; Thomson Peter; Lewis Gemma; Hill Sally A
AUTHOR ADDRESS: (a)Magdalen Centre, Angiogene Pharmaceuticals Ltd., Oxford Science Park, Oxford, OX4 4GA, UK**UK E-Mail: pdd@angiogene.co.uk
JOURNAL: International Journal of Radiation Oncology Biology Physics 54 (5):p1532-1536 December 1 2002 2002
MEDIUM: print
ISSN: 0360-3016
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 8/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13793277 BIOSIS NO.: 200200422098
Targeted delivery of agents designed to manipulate **nitric oxide** production in tumours.
AUTHOR: Everett Steven A(a); Moody Christopher J; Naylor Matthew A(a); Wardman Peter(a)
AUTHOR ADDRESS: (a)Gray Cancer Institute, Mount Vernon Hospital, Northwood, PO Box 100, Middlesex, HA6 2JR**UK
JOURNAL: Nitric Oxide 6 (4):p383-384 June, 2002
MEDIUM: print
CONFERENCE/MEETING: Second International Conference on Biology, Chemistry and Therapeutic Applications Prague, Czech Republic June 16-20, 2002
ISSN: 1089-8603
RECORD TYPE: Citation
LANGUAGE: English

- end of record -

?

Display 8/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13409512 BIOSIS NO.: 200200038333
Tumor **nitric oxide** levels and vascular targeting with **combretastatin** A-4-P.
AUTHOR: Tozer Gillian Mary(a); Prise Vivien Elaine(a); Wilson Ian(a)
AUTHOR ADDRESS: (a)Gray Laboratory Cancer Research Trust, Middlesex**UK
JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 42p824 March, 2001
MEDIUM: print
CONFERENCE/MEETING: 92nd Annual Meeting of the American Association for Cancer Research New Orleans, LA, USA March 24-28, 2001
ISSN: 0197-016X
RECORD TYPE: Citation

LANGUAGE: English

- end of record -

?

Display 8/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13244597 BIOSIS NO.: 200100451746
Mechanisms associated with tumor vascular shut-down induced by **combretastatin** A-4 phosphate: Intravital microscopy and measurement of vascular permeability.
AUTHOR: Tozer Gillian M(a); Prise Vivien E; Wilson John; Cemazar Maja; Shan Siqing; Dewhirst Mark W; Barber Paul R; Vojnovic Borivoj; Chaplin David J
AUTHOR ADDRESS: (a)Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR: tozer@graylab.ac.uk**UK
JOURNAL: Cancer Research 61 (17):p6413-6422 September 1, 2001
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

- end of record -

?

Display 8/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12676397 BIOSIS NO.: 200000429899
Determinants of anti-vascular action by **combretastatin** A-4 phosphate: Role of **nitric oxide**.
AUTHOR: Parkins C S(a); Holder A L; Hill S A; Chaplin D J; Tozer G M
AUTHOR ADDRESS: (a)Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR**UK
JOURNAL: British Journal of Cancer 83 (6):p811-816 September, 2000
MEDIUM: print
ISSN: 0007-0920
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

- end of record -

?

Display 8/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11972059 BIOSIS NO.: 199900225372
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues.
AUTHOR: Tozer Gillian M(a); Prise Vivien E; Wilson John; Locke Rosalind J; Vojnovic Borivoj; Stratford Michael R L; Dennis Madeleine F; Chaplin David J
AUTHOR ADDRESS: (a)Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Nort**UK
JOURNAL: Cancer Research 59 (7):p1626-1634 April 1, 1999
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

SUMMARY LANGUAGE: English

- end of record -

?
Display 8/3/8 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

10178633 Genuine Article#: 491RE No. References: 0
Title: Enhancement of **combretastatin** A4 phosphate activity by **nitric oxide synthase** inhibitors of different structural classes.
Author(s): Davis PD; Thomson P; Naylor MA; Nolan J; Lewis GS; Hill SA
Corporate Source: Angiogene Pharmaceut Ltd,Aston Rowant//England/; Gray Lab Canc Res Trust,Northwood/Middx/England/
Journal: CLINICAL CANCER RESEARCH, 2001, V7, N11,S (NOV), P3656S-3656S
ISSN: 1078-0432 Publication date: 20011100
Publisher: AMER ASSOC CANCER RESEARCH, PO BOX 11806, BIRMINGHAM, AL 35202 USA
Language: English Document Type: MEETING ABSTRACT

- end of record -

?
Display 8/3/9 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11644711 EMBASE No: 2002216312
Small-molecule, tubulin-binding compounds as vascular targeting agents
Marx M.A.
Dr. M.A. Marx, Pfizer Global Research/Development, Pfizer Corporation, Eastern Point Road, Groton, CT 06340 United States
Expert Opinion on Therapeutic Patents (EXPERT OPIN. THER. PAT.) (United Kingdom) 2002, 12/6 (769-776)
CODEN: EOTPE ISSN: 1354-3776
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 38

- end of record -

?
Display 8/3/10 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

11610615 EMBASE No: 2002182701
Angiogenesis: From the molecular mechanisms to the development of new drugs
Morbidelli L.; Donnini S.; D'Amore V.; Ziche M.
L. Morbidelli, Istituto di Scienze Farmacologiche, Universita di Siena, Siena Italy
Acta Medica Romana (ACTA MED. ROM.) (Italy) 2001, 39/2 (238-246)
CODEN: AMROB ISSN: 0001-6098
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH; ITALIAN
NUMBER OF REFERENCES: 24

- end of display -

?
>>>Page beyond end of display invalid
? d s8/9/6
Display 8/9/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

12676397 BIOSIS NO.: 200000429899
Determinants of anti-vascular action by **combretastatin** A-4 phosphate: Role of **nitric oxide**.
AUTHOR: Parkins C S(a); Holder A L; Hill S A; Chaplin D J; Tozer G M
AUTHOR ADDRESS: (a)Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR**UK
JOURNAL: British Journal of Cancer 83 (6):p811-816 September, 2000
MEDIUM: print
ISSN: 0007-0920
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: The anti-vascular action of the tubulin binding agent **combretastatin** A-4 phosphate (CA-4-P) has been quantified in two

-more-

?
Display 8/9/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma SaS. The functional vascular volume, assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumour types, although the degree of reduction was very different in the two tumours. The SaS tumour, which has a higher **nitric oxide synthase** (NOS) activity than the CaNT tumour, showed apprx10-fold greater resistance to vascular damage by CA-4-P. This is consistent with our previous findings, which showed that NO exerts a protective action against this drug. Simultaneous administration of CA-4-P with a NOS inhibitor, Nomega-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumour types. Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects. Following treatment with CA-4-P, neutrophil infiltration into the tumours, measured by myeloperoxidase (MPO) activity, was significantly increased. Levels of MPO activity also correlated with the levels of vascular injury and cytotoxicity measured in both tumour types. Neutrophilic MPO generates

-more-

?
Display 8/9/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

free radicals and may therefore contribute to the vascular damage associated with CA-4-P treatment. MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration. The data are consistent with the hypothesis that neutrophil action contributes to vascular injury by CA-4-P and that NO generation acts to protect the tumour vasculature against CA4-P-induced injury. The protective effect of NO is probably associated with an anti-neutrophil action.

REGISTRY NUMBERS: 10102-43-9: **NITRIC OXIDE**; 125978-95-2: **NITRIC OXIDE SYNTHASE**
DESCRIPTORS:
MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Cardiovascular System (Transport and Circulation); Tumor Biology
BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata,

Animalia

-more-

?
Display 8/9/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.
ORGANISMS: CaNT cell line (Muridae)--murine breast adenocarcinoma cells; SaS cell line (Muridae)--murine round sarcoma cells
ORGANISMS: PARTS ETC: neutrophils--blood and lymphatics, immune system, infiltration
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates
CHEMICALS & BIOCHEMICALS: N-omega-nitro-L-arginine; **combretastatin** A-4 phosphate {CA-4-P}--anti-vascular action, tubulin binding agent; **nitric oxide**; **nitric oxide synthase**
MISCELLANEOUS TERMS: cytotoxicity; vascular damage
CONCEPT CODES:
34502 Immunology and Immunochemistry-General; Methods
02506 Cytology and Cytochemistry-Animal
10060 Biochemical Studies-General
10802 Enzymes-General and Comparative Studies; Coenzymes
14504 Cardiovascular System-Physiology and Biochemistry

-more-

?
Display 8/9/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.
15002 Blood, Blood-Forming Organs and Body Fluids-Blood and Lymph Studies
15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies
24003 Neoplasms and Neoplastic Agents-Immunology
24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects
34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology
BIOSYSTEMATIC CODES:
86375 Muridae

- end of display -

? e au=pero ronald

Ref	Items	Index-term
E1	2	AU=PERO RON W
E2	4	*AU=PERO RONALD
E3	62	AU=PERO RONALD W
E4	2	AU=PERO RS
E5	1	AU=PERO RT
E6	211	AU=PERO RW
E7	2	AU=PERO S
E8	14	AU=PERO S C
E9	7	AU=PERO S.C.
E10	9	AU=PERO SC
E11	12	AU=PERO SILVA A
E12	1	AU=PERO SILVA A.

Enter P or PAGE for more

? e au=pero, ronald

Ref	Items	Index-term
E1	1	AU=PERO, RON W.
E2	8	*AU=PERO, RONALD

```
E3          2  AU=PERO, RONALD W
E4        124  AU=PERO, RONALD W.
E5          1  AU=PERO, RONALD WILLIAM
E6          1  AU=PERO, RW
E7          1  AU=PERO, S. C.
E8          4  AU=PERO, STEPHANIE C.
E9          1  AU=PERO, SUZANNE FRITTS
E10         1  AU=PEROBA CEN
E11         1  AU=PEROBA M A B
E12         1  AU=PEROBA M.A.B.

          Enter P or PAGE for more
? s e4 and combretastatin
             124  AU=PERO, RONALD W.
            1835  COMBRETASTATIN
      S9       0  AU='PERO, RONALD W.' AND COMBRETASTATIN
?
```